ArticleiScience2026
Untargeted metabolomics reveals the effect of MYH9 on the metabolism of vascular endothelial cells.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MYH9 plays a crucial role in vascular endothelial cells (VECs) and is a significant cause of abnormal bleeding in MYH9-related diseases (MYH9-RDs). However, research on how MYH9 regulates VECs has been limited so far, and there is a lack of biomarkers to assist in diagnosing MYH9-RD. In this study, we discovered that inhibiting MYH9 (via Blebbistatin, Bleb) or knocking down its gene significantly impairs angiogenesis, vasculogenesis, and VEC functions, including migration and tube formation. Further untargeted metabolomics identified 152 differential metabolites, such as sulfate and glycerophosphocholine, in MYH9-knockdown VECs, enriched in sulfur metabolism and glycerophospholipid metabolism. Importantly, MYH9 overexpression in VECs validated these key metabolites and pathways. These results reveal a close association between metabolites, such as sulfate and MYH9-RD vascular abnormalities, and provide potential diagnostic biomarkers and therapeutic targets for MYH9-RD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.